- Home
- V vs ABBV Comparison
V vs ABBV Comparison
Compare V & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | V | ABBV |
|---|---|---|
| Founded | 1958 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 613.8B | 358.5B |
| IPO Year | 2007 | 2012 |
Fundamental Metrics
Financial Performance| Metric | V | ABBV |
|---|---|---|
| Price | $329.23 | $215.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 18 |
| Target Price | ★ $394.18 | $253.71 |
| AVG Volume (30 Days) | ★ 6.8M | 3.4M |
| Earning Date | 04-28-2026 | 04-29-2026 |
| Dividend Yield | 0.80% | ★ 3.39% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.39 |
| Revenue | $21,846,000,000.00 | ★ $61,160,000,000.00 |
| Revenue This Year | $13.85 | $11.87 |
| Revenue Next Year | $10.36 | $8.12 |
| P/E Ratio | ★ $30.09 | $566.36 |
| Revenue Growth | N/A | ★ 8.57 |
| 52 Week Low | $293.89 | $181.75 |
| 52 Week High | $359.66 | $244.81 |
Technical Indicators
Market Signals| Indicator | V | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 55.31 | 47.62 |
| Support Level | $320.32 | $210.34 |
| Resistance Level | $339.01 | $218.44 |
| Average True Range (ATR) | 7.02 | 5.21 |
| MACD | 0.69 | -0.74 |
| Stochastic Oscillator | 73.36 | 34.73 |
Price Performance
Historical ComparisonAbout V Visa Inc.
Visa is the largest payment processor in the world. In fiscal 2025, it processed almost $17 trillion in total volume. Visa operates in over 200 countries and processes transactions in over 160 currencies. Its systems are capable of processing over 65,000 transactions per second.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.